243
Participants
Start Date
November 19, 2020
Primary Completion Date
August 4, 2022
Study Completion Date
September 10, 2024
Dostarlimab
Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
Pembrolizumab
Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
Chemotherapy
"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
GSK Investigational Site, Changhua
GSK Investigational Site, Florida
GSK Investigational Site, La Plata
GSK Investigational Site, Taipei
GSK Investigational Site, Berlin
GSK Investigational Site, Caen
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Fairfax
GSK Investigational Site, Jaén
GSK Investigational Site, Brescia
GSK Investigational Site, Oldenburg
GSK Investigational Site, Lugo
GSK Investigational Site, Cheongju Chungcheongbuk-do
GSK Investigational Site, Málaga
GSK Investigational Site, Aviano PN
GSK Investigational Site, Pessac
GSK Investigational Site, Immenhausen
GSK Investigational Site, Seville
GSK Investigational Site, Saint-Herblain
GSK Investigational Site, Cincinnati
GSK Investigational Site, Pusan
GSK Investigational Site, Cologne
GSK Investigational Site, Valenciennes
GSK Investigational Site, Frankfurt
GSK Investigational Site, Le Mans
GSK Investigational Site, Denver
GSK Investigational Site, Napoli
GSK Investigational Site, Limoges
GSK Investigational Site, Craiova
GSK Investigational Site, Floreşti
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Ciudad Autonoma de Buenos Aire
GSK Investigational Site, Córdoba
GSK Investigational Site, La Rioja
GSK Investigational Site, Pergamino
GSK Investigational Site, Rosario
GSK Investigational Site, San Juan
GSK Investigational Site, Viedma
GSK Investigational Site, Barretos
GSK Investigational Site, Fortaleza
GSK Investigational Site, Natal
GSK Investigational Site, Rio de Janeiro
GSK Investigational Site, São Paulo
GSK Investigational Site, Vitória
GSK Investigational Site, Roma
GSK Investigational Site, Bydgoszcz
GSK Investigational Site, Lodz
GSK Investigational Site, Lublin
GSK Investigational Site, Olsztyn
GSK Investigational Site, Poznan
GSK Investigational Site, Bucharest
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY